Azacitidine
BPDCN
Therapeutic Advances in Childhood Leukemia ConsortiumSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
34 Active assets in the BPDCN cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tagraxofusp French Innovative Leukemia Organisation | Phase 2 | BB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 2 | BB |
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
METHOTREXATE Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | BB |
Fludarabine Therapeutic Advances in Childhood Leukemia Consortium | Phase 2 | B |
View all 48 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →